Sekunjalo Investments Limited - Sekunjalo Enters Marketing And Distribution

Sekunjalo Investments Limited - Sekunjalo Enters Marketing And Distribution     
Agreement With Unichem                                                          
Sekunjalo Investments Limited                                                   
(Incorporated in the Republic of South Africa)                                  
(Registration number 1996/006093/06)                                            
Share code: SKJ & ISIN: ZAE000017893                                            
("Sekunjalo" or "the company")                                                  
Media Release:                                                                  
SEKUNJALO ENTERS MARKETING & DISTRIBUTION AGREEMENT WITH UNICHEM                
Sekpharma, the Health Care subsidiary of Sekunjalo Investments Limited,         
announced today that it has entered a marketing and distribution agreement with 
one of the leading India"s pharmaceutical multinationals - Unichem Laboratories 
Limited for the Southern African market.                                        
Mr. Muzi Nkosi, CEO of Sekunjalo Healthcare said that this agreement with       
Unichem is significant keeping in view the increasing demand for quality and    
affordable generics in the global markets including South Africa. This          
arrangement is expected to contribute significantly to the revenue flows of     
Sekpharma over the next 5 years and will strengthen the portfolio of the ethical
and generic range being offered by Sekpharma. Unichem has in its portfolio a    
range of generic products that span the various therapeutic categories being    
prescribed by the physician. Many of these products are under the registration  
process and are expected to be launched over the next couple of years in South  
Africa.                                                                         
The initial 5 products which this partnership is planning to launch in South    
Africa over the next 6 months represents a market potential of R110 million with
excellent growth prospects.                                                     
Unichem Laboratories Limited is an Indian pharmaceutical company with vertically
integrated operations. The company develops, manufactures and markets finished  
dosage formulations and active pharmaceutical ingredients in anti-infective,    
cardiovascular, psychiatry and neurology in India and overseas. Unichem is also 
engaged in research and development of new drug delivery systems and development
of non-infringing process for active pharmaceutical ingredients.                
In South Africa, it operates through its subsidiary company - Unichem SA (Pty)  
Ltd, which is the holding company for all the registrations. Unichem does not   
plan to put up any infrastructure in South Africa, instead would depend on this 
relationship to market the products in the region.  It is the intention of the  
company to be in line with the current changes in the South African climate     
which places more emphasis on black empowerment and which is why it chose to    
partner with one of the leading black owned pharmaceutical marketing companies. 
Mr. Nkosi said that this relationship is strategic and would enable Sekpharma to
tap into the Unichem portfolio and position itself as a serious player in the   
pharmaceutical sector. He also stated that this agreement follows the           
acquisition  by Sekpharma of the pharmaceutical brands of Glaxo Smith Kline in  
2000 which include the leading injectable antibiotic - Fortum, The dermatology  
range - Dermovate, Betnovate, Eumovate & The Asthma range - that include        
Becotide and Becloforte.                                                        
Mr. Nkosi also announced that Sekunjalo Healthcare would aggressively increase  
its position over the next few months and has identified the area of infectious 
diseases to offer affordable solutions to the people of Southern Africa.        
Dr. Surve, the CEO of Sekunjalo Investments Limited congratulates Mr Nkosi for  
growing Sekpharma and for his acquisitive growth strategy. Dr. Surve has said   
that Mr. Nkosi is leading the Sekpharma team into a potential listing on the JSE
and Sekpharma has been approached to consider listing with other listed         
pharmaceutical companies. Dr. Surve also stated that Mr. Nkosi, the CEO of      
Sekpharma and Sekunjalo Healthcare for the last 3 years has also been recently  
appointed to the main board of Sekunjalo Investments Limited, the holding       
company of the group.                                                           
For further information                                                         
Melody Mjila                                                                    
Group Communications Manager                                                    
Sekunjalo Investments Limited.                                                  
Tel: 021 658 2700                                                               
Date: 25/08/2005 12:10:28 PM Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department